Lakefront Biotherapeutics NV (LKFT)Healthcare | Biotechnology | Mechelen, Belgium | NasdaqGS
28.35 USD
+0.03
(0.106%)
⇧
(May 29, 2026, 4 p.m.
EDT)
After hours: 28.35 |
Hot Take ↕ | May 25, 2026, 3:48 a.m. EDT
The investment case here is fundamentally broken by a massive contraction in business scale. While the balance sheet appears pristine with negligible debt and a fortress-like current ratio, the company is hemorrhaging revenue, which has plummeted by nearly 92% year-over-year. This collapse in top-line growth is the primary driver for the low ratings; without a viable path to restoring demand, the impressive cash reserves will eventually deplete, turning this into a classic value trap where the cheap price reflects a dying business rather than a bargain. The stock is trading at a low P/E simply because earnings are shrinking so fast, masking the reality that the core product or market is failing. On the short end, the lack of meaningful options flow and the weak statistical forecast suggest no immediate catalyst to reverse this trend, leaving the stock stuck in a downtrend defined by deteriorating fundamentals. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.129547 |
| AutoTheta | 0.134573 |
| AutoETS | 0.135006 |
| AutoARIMA | 0.135008 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.126 |
| Excess Kurtosis | -0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.198 |
| Revenue per Share | 0.79185 |
| Market Cap | 1,868,182,016 |
| Trailing P/E | 3.29 |
| Forward P/E | -9.44 |
| Beta | 0.12 |
| Profit Margins | 46.83% |
| Previous Name | Galapagos NV |
| Website | https://lakefrontbio.com |
As of May 25, 2026, 3:48 a.m. EDT: Speculators are positioning defensively with significant open interest in ATM puts expiring in June, suggesting a fear of downside volatility. Conversely, call activity is sparse and concentrated in October strikes above the current price, indicating limited near-term bullish conviction despite the low implied volatility environment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.015299022 |
| Address1 | SchaliEnhoevedreef 20 T |
| All Time High | 274.03 |
| All Time Low | 12.91 |
| Ask | 28.39 |
| Ask Size | 1 |
| Average Analyst Rating | 3.5 - Hold |
| Average Daily Volume10 Day | 145,520 |
| Average Daily Volume3 Month | 165,969 |
| Average Volume | 165,969 |
| Average Volume10Days | 145,520 |
| Beta | 0.115 |
| Bid | 28.53 |
| Bid Size | 1 |
| City | Mechelen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Belgium |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.35 |
| Current Ratio | 30.478 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,778,803,200 |
| Day High | 28.69 |
| Day Low | 28.18 |
| Debt To Equity | 0.198 |
| Display Name | Lakefront Biotherapeutics |
| Ebitda | 662,956,480 |
| Ebitda Margins | 0.63517 |
| Enterprise To Ebitda | -1.674 |
| Enterprise To Revenue | -1.063 |
| Enterprise Value | -1,109,600,000 |
| Eps Current Year | -2.295 |
| Eps Forward | -3.0022705 |
| Eps Trailing Twelve Months | 8.62 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 32 1 534 29 01 |
| Fifty Day Average | 28.784 |
| Fifty Day Average Change | -0.43400002 |
| Fifty Day Average Change Percent | -0.015077821 |
| Fifty Two Week Change Percent | -1.5299022 |
| Fifty Two Week High | 37.78 |
| Fifty Two Week High Change | -9.429998 |
| Fifty Two Week High Change Percent | -0.24960293 |
| Fifty Two Week Low | 26.42 |
| Fifty Two Week Low Change | 1.9300003 |
| Fifty Two Week Low Change Percent | 0.07305073 |
| Fifty Two Week Range | 26.42 - 37.78 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,330,353,000,000 |
| Float Shares | 44,538,512 |
| Forward Eps | -3.0022705 |
| Forward P E | -9.442854 |
| Free Cashflow | 210,970,496 |
| Full Exchange Name | NasdaqGS |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.68533 |
| Gross Profits | 715,315,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.25354 |
| Held Percent Institutions | 0.22670999 |
| Implied Shares Outstanding | 65,897,071 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. |
| Long Name | Lakefront Biotherapeutics NV |
| Market | us_market |
| Market Cap | 1,868,182,016 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_1716658 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-05-29 |
| Net Income To Common | 487,931,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,846,497,501 |
| Number Of Analyst Opinions | 2 |
| Open | 28.25 |
| Operating Cashflow | -301,599,008 |
| Operating Margins | -9.82919 |
| Payout Ratio | 0.0 |
| Phone | 32 1 534 29 00 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 28.35 |
| Post Market Time | 1,780,085,405 |
| Prev Name | Galapagos NV |
| Previous Close | 28.32 |
| Price Eps Current Year | -12.352941 |
| Price Hint | 2 |
| Price To Sales Trailing12 Months | 1.7898716 |
| Profit Margins | 0.46828997 |
| Quick Ratio | 30.235 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.5 |
| Region | US |
| Regular Market Change | 0.030000687 |
| Regular Market Change Percent | 0.10593463 |
| Regular Market Day High | 28.69 |
| Regular Market Day Low | 28.18 |
| Regular Market Day Range | 28.18 - 28.69 |
| Regular Market Open | 28.25 |
| Regular Market Previous Close | 28.32 |
| Regular Market Price | 28.35 |
| Regular Market Time | 1,780,084,801 |
| Regular Market Volume | 117,359 |
| Return On Assets | 0.10655 |
| Return On Equity | 0.16261 |
| Revenue Growth | -0.914 |
| Revenue Per Share | 0.79185 |
| Sand P52 Week Change | 0.2794361 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,897,071 |
| Shares Percent Shares Out | 0.024300002 |
| Shares Short | 1,602,902 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 1,096,114 |
| Short Name | Lakefront Biotherapeutics |
| Short Percent Of Float | 0.0396 |
| Short Ratio | 10.53 |
| Source Interval | 15 |
| Symbol | LKFT |
| Target High Price | 27.777779 |
| Target Low Price | 19.062609 |
| Target Mean Price | 23.420193 |
| Target Median Price | 23.420193 |
| Total Cash | 2,982,240,000 |
| Total Cash Per Share | 45.256 |
| Total Debt | 6,435,000 |
| Total Revenue | 1,043,752,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 8.62 |
| Trailing P E | 3.2888632 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.78825 |
| Two Hundred Day Average Change | -3.4382496 |
| Two Hundred Day Average Change Percent | -0.108161025 |
| Type Disp | Equity |
| Volume | 117,359 |
| Website | https://lakefrontbio.com |
| Zip | 2,800 |